OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema
- First Posted Date
- 2010-05-03
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01114828
Study of SPM 962 in Patients With Restless Legs Syndrome (RLS)
Phase 3
Completed
- Conditions
- Idiopathic Restless Legs Syndrome
- Interventions
- Drug: Placebo of SPM 962
- First Posted Date
- 2010-03-10
- Last Posted Date
- 2014-06-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 284
- Registration Number
- NCT01084551
Safety and Pharmacokinetic Study of C13-URA in Healthy Volunteers
Phase 1
Completed
- Conditions
- Gastroparesis
- Interventions
- Drug: [2-13C] uracil, placebo
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2010-07-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 8
- Registration Number
- NCT01074710
- Locations
- 🇺🇸
Covance Clinical Pharmacology, Inc., Madison, Wisconsin, United States
A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema
- First Posted Date
- 2010-01-15
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT01050530
A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT01048788
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 13
- Registration Number
- NCT01022424
A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 191
- Registration Number
- NCT00989573
To Investigate the Efficacy and Safety of OPC-6535 in Chronic Obstructive Pulmonary Disease (COPD) Patients
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: placebo
- First Posted Date
- 2009-06-10
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 771
- Registration Number
- NCT00917150
Confirmatory Study of OPC-12759 Ophthalmic Suspension
Phase 3
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: Hyalein Mini Ophthalmic solution
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2013-12-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 188
- Registration Number
- NCT00885079
- Locations
- 🇯🇵
Kanto region, Tokyo, Japan
🇯🇵Kansai region, Osaka, Japan
🇯🇵Kyushu region, Kagoshima, Japan
Long-Term Administration Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: OPC-14597 (Aripiprazole)
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 155
- Registration Number
- NCT00882362
© Copyright 2025. All Rights Reserved by MedPath